– USA, CA – Nurix Therapeutics, Inc. (Nasdaq: NRIX), focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, announced the appointment of Dr. Roger Dansey (M.D.) to its board of directors.
About Dr. Roger Dansey
Dr. Roger Dansey, who previously served as CDO and Chief Oncology Officer of Pfizer Oncology and as CMO and interim CEO of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization.
Dr. Roger Dansey served as the Chief Development Officer and Chief Oncology Officer of Pfizer Oncology from January 2024 until his retirement in March 2025. He served as President, Research and Development of Seagen from November 2022 until Pfizer acquired Seagen in December 2023. Dr. Dansey was interim CEO of Seagen from May 2022 until November 2022 and served as CMO at Seagen from May 2018 until May 2022. Earlier in his career, Dr. Dansey held senior clinical development leadership positions, including Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types, Vice President of Oncology Clinical Research at Gilead Sciences, and the Global Development Lead for Xgeva (denosumab) at Amgen. Before joining the industry, Dr. Dansey was an associate professor of hematology and oncology at the Karmanos Cancer Institute in Detroit.
Dr. Dansey serves on the boards of directors of Bicycle Therapeutics plc, Inovio Pharmaceuticals, Inc., MycRX Pharma, Ottimo Pharma Ltd, and Shasqi Inc.
Dr. Dansey holds an M.D. from the University of Witwatersrand, Johannesburg, South Africa.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical-stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types, including T cells and NK cells. Nuriis alsois advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California.
For more: https://www.nurixtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.